Concepedia

Timothy M. Lestingi

TM

Statistics

Publications

12

Citations

1.1K

H-Index

12

Active since

1993

Affiliations

Advocate Lutheran General Hospital(Current)

University of Chicago

Oncology Specialists

University of Illinois Chicago

Timothy M. Lestingi is an author at Advocate Lutheran General Hospital specializing in medicine, urology, and oncology.

Top concepts

Publications per year

1993–2019

12

Publications

12

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.

E Gupta, Timothy M. Lestingi, Rosemarie Mick et al. · PubMed · 1994 · 506 citations

, , +21

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.

E Gupta, Rosemarie Mick, Xiaolin Wang et al. · Journal of Clinical Oncology · 1997 · 181 citations

Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma

Jon Richards, Danielle Gale, Nilesh Mehta et al. · Journal of Clinical Oncology · 1999 · 102 citations

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

, , +9

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

Kimberly Kruczek, Megan Ratterman, Kathy Tolzien et al. · British Journal of Cancer · 2013 · 54 citations · Full text

1–5 of 12